Bavarian Nordic A/S

U.S. patent granted for modified virus ankara

Published in Biotech Law Weekly, August 5th, 2005

Bavarian Nordic A/S (BAVA) announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company that further strengthens its intellectual property position on modified virus Ankara (MVA).

The new patent ("Modified vaccinia ankara virus variant" - U.S. Patent No. 6,913,752) grants claims that are directed to an MVA-based vaccinia virus having specific improved properties, such as that it does not replicate in human cells, compared to other MVA strains which may replicate in certain human cells.

This new patent, as well as the USPTO patent received by the company on MVA-BN in 2004, are based on the same patent priority from a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2005-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry